VEVZUO™ Denosumab 120 mg/1.7 mL Solution for Injection in Vial

NAME OF THE MEDICINAL PRODUCT

Vevzuo™ Denosumab 120 mg/1.7 mL Solution for Injection in Vial

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 120 mg of Denosumab in 1.7 mL of solution (70 mg/mL).

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology.

Excipient with known effects

Each 1.7 mL of solution contains 79.9 mg sorbitol

List of Excipients

Acetic Acid Glacial, Sodium Acetate Trihydrate, Sodium Hydroxide, Sorbitol, Polysorbate 20, Water for Injections.

PHARMACEUTICAL FORM

Solution for subcutaneous injection.

Clear to slightly opalescent, colourless to pale yellow solution. VEVZUO is a biosimilar product of XGEVA.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties

Pharmacotherapeutic group: Drugs for treatment of bone diseases – other drugs affecting bone structure and mineralisation, ATC code: M05BX04

Mechanism of Action

Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) exists as a transmembrane or soluble protein. RANKL is essential for the formation, function and survival of osteoclasts, the sole cell type responsible for bone resorption. Increased osteoclast activity, stimulated by RANKL, is a key mediator of bone destruction in metastatic bone disease and multiple myeloma. Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction.

Giant cell tumours of bone are characterised by neoplastic stromal cells expressing Receptor Activator of Nuclear Factor Kappa B (RANK) ligand and osteoclast-like giant cells expressing RANK. In patients with giant cell tumour of bone, Denosumab binds to RANK ligand, significantly reducing or eliminating osteoclast-like giant cells. Consequently, osteolysis is reduced and proliferative tumour stroma is replaced with non-proliferative, differentiated, densely woven new bone.

Pharmacodynamics effects

In phase II clinical studies of patients with advanced malignancies involving bone, subcutaneous (SC) dosing of Denosumab administered either every 4 weeks (Q4W) or every 12 weeks resulted in a rapid reduction in markers of bone resorption (uNTX/Cr, serum CTx), with median reductions of approximately 80% for uNTX/Cr occurring within 1 week regardless of prior bisphosphonate therapy or baseline uNTx/Cr level. In phase III clinical trials of patients with advanced malignancies Page 2 of 19 involving bone, median uNTx/Cr reductions of approximately 80% were maintained through 49 weeks of Denosumab treatment (120 mg every Q4W).

Immunogenicity

In clinical studies, neutralising antibodies have not been observed for Denosumab in advanced cancer patients or giant cell tumour of bone patients. Using a sensitive immunoassay < 1% of patients treated with Denosumab for up to 3 years tested positive for non-neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.

Information below refers to Xgeva

Clinical efficacy and safety in patients with bone metastases from solid tumours

Efficacy and safety of 120 mg Denosumab SC every 4 weeks or 4 mg Zoledronic Acid (dose-adjusted for reduced renal function) IV every 4 weeks were compared in three randomised, double-blind, active-controlled studies, in IV-bisphosphonate naïve patients with advanced malignancies involving bone: adults with breast cancer (study 1), other solid tumours or multiple myeloma (study 2), and castrate-resistant prostate cancer (study 3). Within these active-controlled clinical trials, safety was evaluated in 5,931 patients. Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned invasive dental procedure, were not eligible for inclusion in these studies. The primary and secondary endpoints evaluated the occurrence of one or more Skeletal Related Events (SREs). In studies demonstrating superiority of Denosumab to Zoledronic Acid, patients were offered open-label Denosumab in a prespecified 2-year extension treatment phase. An SRE was defined as any of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

Denosumab reduced the risk of developing a SRE, and developing multiple SREs (first and subsequent) in patients with bone metastases from solid tumours.

Efficacy results from study 1, 2 and 3 are presented in Table 1.

Table 1: Efficacy results in patients with advanced malignancies involving bone

Study 1 breast cancer		Study 2 other solid tumours** or multiple myeloma		Study 3 prostate cancer		Combined advanced cancer	
Denosumab	Zoledronic Acid	Denosumab	Zoledronic Acid	Denosumab	Zoledronic Acid	Denosumab	Zoledronic Acid
N	1,026	1,020	886	890	950	951	2,862	2,861
First SRE								
Median time (months)	NR	26.4	20.6	16.3	20.7	17.1	27.6	19.4
Difference in median time (months)	NA		4.2		3.5		8.2	
HR (95% CI) / RRR (%)	0.82 (0.71, 0.95) / 18		0.84 (0.71, 0.98) / 16		0.82 (0.71, 0.95) / 18		0.83 (0.76, 0.90) / 17	
Non-inferiority / Superiority p-values	< 0.0001† / 0.0101†		0.0007† / 0.0619†		0.0002† / 0.0085†		< 0.0001 / < 0.0001	
Proportion of subjects (%)	30.7	36.5	31.4	36.3	35.9	40.6	32.6	37.8
First and subsequent SRE*								
Mean number/ patient	0.46	0.60	0.44	0.49	0.52	0.61	0.48	0.57

NR = not reached; NA = not available; HCM = hypercalcaemia of malignancy; SMR = skeletal morbidity rate;

HR = Hazard Ratio; RRR = Relative Risk Reduction; †Adjusted p-values are presented for studies 1, 2 and 3 (first SRE and first and subsequent SRE endpoints); *Accounts for all skeletal events over time; only events occurring ≥ 21 days after the previous event are counted.

** Including NSCLC, renal cell cancer, colorectal cancer, small cell lung cancer, bladder cancer, head and neck cancer, GI/genitourinary cancer and others, excluding breast and prostate cancer.

Figure 1. Kaplan-Meier plots of time to first on-study SRE

Dmab = Denosumab 120 mg Q4W

ZA = Zoledronic Acid 4 mg Q4W

N = Number of subjects randomised

* = Statistically significant for superiority; ** = statistically significant for non-inferiority

Disease progression and overall survival with bone metastases from solid tumours

Disease progression was similar between Denosumab and Zoledronic acid in all three studies and in the pre-specified analysis of all three studies combined.

In studies 1, 2 and 3, overall survival was balanced between Denosumab and Zoledronic Acid in patients with advanced malignancies involving bone: patients with breast cancer (hazard ratio and 95% CI was 0.95 [0.81, 1.11]), patients with prostate cancer (hazard ratio and 95% CI was 1.03 [0.91, 1.17]), and patients with other solid tumours or multiple myeloma (hazard ratio and 95% CI was 0.95 [0.83, 1.08]). A post-hoc analysis in study 2 (patients with other solid tumours or multiple myeloma) examined overall survival for the 3 tumour types used for stratification (non-small cell lung cancer, multiple myeloma, and other). Overall survival was longer for Denosumab in non-small cell lung cancer (hazard ratio [95% CI] of 0.79 [0.65, 0.95]; n = 702) and longer for Zoledronic Acid in multiple myeloma (hazard ratio [95% CI] of 2.26 [1.13, 4.50]; n = 180) and similar between Denosumab and Zoledronic Acid in other tumour types (hazard ratio [95% CI] of 1.08 (0.90, 1.30); n = 894). This study did not control for prognostic factors and anti-neoplastic treatments. In a combined pre-specified analysis from studies 1, 2 and 3, overall survival was similar between Denosumab and Zoledronic Acid (hazard ratio and 95% CI 0.99 [0.91, 1.07]).

Effect on pain

The time to pain improvement (i.e. ≥ 2-point decrease from baseline in BPI-SF worst pain score) was similar for Denosumab and Zoledronic Acid in each study and the integrated analyses. In a post-hoc analysis of the combined dataset, the median time to worsening pain (> 4-point worst pain score) in patients with mild or no pain at baseline was delayed for Denosumab compared to Zoledronic Acid (198 versus 143 days) (p = 0.0002).

Clinical efficacy in patients with multiple myeloma

Denosumab was evaluated in an international, randomised (1:1), double-blind, active-controlled study comparing Denosumab with Zoledronic Acid in patients with newly diagnosed multiple myeloma, study 4.

In this study, 1,718 multiple myeloma patients with at least one bone lesion were randomised to receive 120 mg Denosumab subcutaneously every 4 weeks (Q4W) or 4 mg Zoledronic Acid intravenously (IV) every 4 weeks (dose-adjusted for renal function). The primary outcome measure was demonstration of non-inferiority of time to first on study skeletal related event (SRE) as compared to Zoledronic Acid. Secondary outcome measures included superiority of time to first SRE, superiority of time to first and subsequent SRE, and overall survival. An SRE was defined as any of the following:

Pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

Across both study arms, 54.5% of patients intended to undergo autologous PBSC transplantation, 95.8% patients utilised/planned to utilise a novel anti-myeloma agent (novel therapies include bortezomib, lenalidomide, or thalidomide) in first-line therapy, and 60.7% of patients had a previous SRE. The number of patients across both study arms with ISS stage I, stage II, and stage III at diagnosis were 32.4%, 38.2%, and 29.3%, respectively.

The median number of doses administered was 16 for Denosumab and 15 for Zoledronic Acid.

Efficacy results from study 4 are presented in Figure 2 and Table 2.

Figure 2. Kaplan-Meier plot for time to first on-study SRE in patients with newly diagnosed multiple myeloma

N = number of subjects randomised

Table 2. Efficacy results for Denosumab compared to Zoledronic Acid in patients with newly diagnosed multiple myeloma

Denosumab (N = 859)	Zoledronic Acid (N = 859)
First SRE	
Number of patients who had SREs (%)	376 (43.8)	383 (44.6)
Median time to SRE (months)	22.8 (14.7, NE)	23.98 (16.56, 33.31)
Hazard ratio (95% CI)	0.98 (0.85, 1.14)
First and subsequent SRE	
Mean number of events/patient	0.66	0.66
Rate ratio (95% CI)	1.01 (0.89, 1.15)
Skeletal morbidity rate per year	0.61	0.62
First SRE or HCM	
Median time (months)	22.14 (14.26, NE)	21.32 (13.86, 29.7)
Hazard ratio (95% CI)	0.98 (0.85, 1.12)
First radiation to bone	
Hazard ratio (95% CI)	0.78 (0.53, 1.14)
Overall survival	
Hazard ratio (95% CI)	0.90 (0.70, 1.16)

NE = not estimable

HCM = hypercalcaemia of malignancy

Clinical efficacy and safety in adults and skeletally mature adolescents with giant cell tumour of bone t

The safety and efficacy of Denosumab was studied in two phase II open-label, single-arm trials (studies 5 and 6) that enrolled 554 patients with giant cell tumour of bone that was either unresectable or for which surgery would be associated with severe morbidity. Patients received 120 mg Denosumab subcutaneously every 4 weeks with a loading dose of 120 mg on days 8 and 15. Patients who discontinued Denosumab then entered the safety follow-up phase for a minimum of 60 months.

Retreatment with Denosumab while in safety follow-up was allowed for subjects who initially demonstrated a response to Denosumab (e.g. in the case of recurrent disease).

Study 5 enrolled 37 adult patients with histologically confirmed unresectable or recurrent giant cell tumour of bone. The main outcome measure of the trial was response rate, defined as either at least 90% elimination of giant cells relative to baseline (or complete elimination of giant cells in cases where giant cells represent < 5% of tumour cells), or a lack of progression of the target lesion by radiographic measurements in cases where histopathology was not available. Of the 35 patients included in the efficacy analysis, 85.7% (95% CI: 69.7, 95.2) had a treatment response to Denosumab. All 20 patients (100%) with histology assessments met response criteria. Of the remaining 15 patients, 10 (67%) radiographic measurements showed no progression of the target lesion.

Study 6 enrolled 535 adult or skeletally mature adolescents with giant cell tumour of bone. Of these patients, 28 were aged 12-17 years. Patients were assigned to one of three cohorts: cohort 1 included patients with surgically unsalvageable disease (e.g. sacral, spinal, or multiple lesions, including pulmonary metastases); cohort 2 included patients with surgically salvageable disease whose planned surgery was associated with severe morbidity (e.g. joint resection, limb amputation, or hemipelvectomy); cohort 3 included patients previously participating in study 5 and rolled over into this study. The primary objective was to evaluate the safety profile of Denosumab in subjects with giant cell tumour of bone. The secondary outcome measures of the study included time to disease progression (based on investigator assessment) for cohort 1 and proportion of patients without any surgery at month 6 for cohort 2.

In cohort 1 at the final analysis, 28 of the 260 treated patients (10.8%) had disease progression. In cohort 2, 219 of the 238 (92.0%; 95% CI: 87.8%, 95.1%) evaluable patients treated with Denosumab had not undergone surgery by month 6. Of the 239 subjects in cohort 2 with baseline target lesion location or on-study location not in lungs or soft tissue, a total of 82 subjects (34.3%) were able to avoid on- study surgery. Overall, efficacy results in skeletally mature adolescents were similar to those observed in adults.

Effect on pain

In the final analysis cohorts 1 and 2 combined, a clinically meaningful reduction in worst pain (i.e. ≥ 2-point decrease from baseline) was reported for 30.8% of patients at risk (i.e. those who had a worst pain score of ≥ 2 at baseline) within 1 week of treatment, and ≥ 50% at week 5. These pain improvements were maintained at all subsequent evaluations.

Paediatric population

In study 6, Denosumab has been evaluated in a subset of 28 adolescent patients (aged 13-17 years) with giant cell tumour of bone who had reached skeletal maturity defined by at least 1 mature long bone (e.g. closed epiphyseal growth plate of the humerus) and body weight ≥ 45 kg. One adolescent subject with surgically unsalvageable disease (N=14) had disease recurrence during initial treatment. Thirteen of the 14 subjects with surgically salvageable disease whose planned surgery was associated with severe morbidity had not undergone surgery by month 6.

Information below refers to biosimilar Vevzuo - Comparative of Vevzuo to Xgeva

Note: Based on the demonstrated analytical similarity to both reference products and the identical mechanism of action of denosumab, the comparative clinical data (Phase 1 pharmacodynamics (PD)/ pharmacokinetics (PK) obtained with Evfraxy–Prolia are considered applicable to Vevzuo–Xgeva, thereby supporting extrapolation to all approved indications of denosumab.

Study B1000- NHV-01- G-01

The Phase I PK comparability study of Bmab 1000-P versus the US-licensed Prolia comprised a randomised, double-blind, two-arm, single-dose, parallel-group study in normal healthy adult participants.

Participants were stratified based on site, ethnicity (Japanese *versus* non-Japanese), body weight (55 to <60 kg for Japanese only, 60-80 kg and 81-95 kg) and gender. Sentinel dosing was used such that 2 cohorts of 2 participants (1 Bmab 1000, 1 Prolia) were dosed at least 24 hours apart and, after confirming that no safety concerns arose. Remaining participants were dosed starting from at least 24 hours later. Post dosing, all participants were followed up for 36 weeks where blood samples were collected at scheduled timepoints for PK, PD, immunogenicity, and safety laboratory assessments. The participants were observed for a 36-week period for safety monitoring. Investigational medicinal product (IMP) was administered by subcutaneous (s.c.) injection.

Following a single s.c. dose of 60 mg Bmab 1000 and of 60 mg Prolia, the mean Cmax, AUC0-t and AUC0-inf, including the partial AUCs (AUC18-85days and AUC113-253days) were comparable between the two treatments group. The tmax, Ct, and the t1/2 were comparable between the Bmab 1000 and Prolia treatment groups. The AUCext(%) was less than 1% following administration of both study treatments reflecting that the PK sampling duration considered for the study was adequate for the estimation of the terminal phase. Statistical analysis demonstrated PK similarity between Bmab 1000 and Prolia as the 90% CIs of geometric least squared means (GLSMs) ratio for primary PK parameters (Cmax, AUC0-t and AUC0-inf), were entirely contained within the predefined bioequivalence range of 0.8000 and 1.2500. Statistical analysis of protein-adjusted primary PK parameters (Cmax/P, AUC0-t/P and AUC0-inf/P) supported PK similarity between Bmab 1000, and Prolia as the 90% CIs of GLSMs ratio (Test/Reference) fell within the bioequivalence range of 0.8000 and 1.2500.

Pharmacodynamic parameters AUEC0-253 days and Emax were secondary endpoints, the CIs of their GMRs are not required to fulfil any equivalence limits. However, the statistical analysis demonstrated PD similarity between Bmab 1000 and Prolia as the 95% CIs of GLSMs ratio for PD parameters (AUEC0-253 days and Emax), were entirely contained within the predefined bioequivalence range of 0.8000 and 1.2500.

The incidence of ADA in the Prolia group and in the Bmab 1000 group closely matched throughout the study: the number of participants with ADA+ increased until D57 (91 [98.9%] participants in the Bmab 1000 group and 87 [93.5%] participants in the Prolia group) and was stable until D85 (91 [98.9%] participants in the Bmab 1000 group and 88 [94.6%] participants in the Prolia group). The number of positive participants then decreased until the end of study (EOS) visit, when 5 (5.4%) participants in the Bmab 1000 group and 2 (2.2%) participants in the Prolia group were positive. The evolution of ADA titers over time in both treatment groups also matched closely.

Overall, 99 (52.4%) participants experienced at least one treatment emergent AE (TEAE), and a total of 221 TEAEs were reported: 110 TEAEs in 47 (50.0%) participants in the Bmab 1000 group and 111 TEAEs in 52 (54.7%) participants in the Prolia group. No grade 3 or higher TEAEs were reported.

Most TEAEs were grade 1, with 38 participants (40.4%) experiencing grade 1 TEAEs in the Bmab 1000 group and 32 participants (33.7%) in the Prolia group. Additionally, grade 2 TEAEs were reported and in 23 participants (24.5%) in the Bmab 1000 group and in 33 participants (34.7%) in the Prolia group. The majority of the events were not related to the study drug. In the Bmab 1000 group, 85 out of 110 TEAEs, reported in 41 (43.6%) participants, were considered not related to treatment, and in the Prolia group, 98 out of 111 TEAEs, reported in 50 (52,6%) participants, were considered not related to the study drug. Incidence of treatment related adverse events were nominally higher in the Bmab1000 group than in the Prolia group; however the number of events in each PT was low. In the Bmab 1000 group, 25 out of 110TEAEs, reported in 16 (17.0%) participants were considered related to treatment, and in the Prolia group, 13 out of 111 TEAEs, in 9 (9.5%) participants, were considered related to treatment.

The type and frequency of the TEAEs were similar in the Bmab 1000 group and in the Prolia group: the most frequent SOCs, reported in at least 5% of the overall population were infections and infestations, gastrointestinal disorders, musculoskeletal and connective tissue disorders, nervous system disorders, and general disorders and administration site conditions. The most frequent PTs reported in at least 5% of the participants in either treatment group were headache, nasopharyngitis, constipation, and back pain. A pregnancy was reported in the female partner of a male participant in Bmab 1000 group. The female partner underwent spontaneous abortion. The event was considered not related to the Bmab 1000. There was no death, no serious AE (SAE), and no TEAEs leading to study discontinuation reported in study participants. No clinically relevant changes in clinical laboratory results, vital signs, or ECG parameters were reported, and no clinically relevant difference was observed between the Bmab 1000 and the Prolia groups. A few participants presented sporadic out-of-range values for some safety parameters; none being considered clinically significant by the Investigator. Mild to moderate injection site reactions were reported in both treatment groups throughout the study; most were below the threshold for TEAE notification.

Following a single s.c. dose of 60 mg Bmab 1000 and 60 mg Prolia, the concentration-time profiles were comparable. Statistical analysis demonstrated PK similarity for PK parameters (AUC0-inf, AUC0-t, and Cmax) between Bmab 1000 and the Prolia as the 90% CIs of GLSMs ratio (Test/Reference) fell within the predefined bioequivalence range of 0.8000 and 1.2500 (i.e., 80.00% and 125.00%). The partial AUC18-85days and AUC113-253days that were characterised to depict the linear /non-linear-TMDD pathway were similar between the treatment groups. PD parameters (AUEC0-253days and Emax) were observed to be similar between the two treatment groups. The point estimates (95% CIs) of Test/Reference GLSMs ratio derived for Emax and AUEC0-253days were entirely contained within the standard bioequivalence range of 0.8000 and 1.2500. A single dose of 60 mg Bmab 1000/Prolia was safe and well tolerated in healthy subjects across the two treatment groups. The majority of the AEs were mild in severity and were considered not related to the study drugs. The incidence of ADA was observed to be similar between the two treatment arms.

The results from this study complement the comparative physical and chemical characterization of Bmab 1000 and Prolia, confirming that the demonstrated analytical comparability translates into highly similar clinical exposure over time i.e. bioequivalence and highly similar pharmacodynamic behaviour of Bmab 1000 and Prolia. Seen in context this study provides additional support for the contention that Bmab 1000 qualifies as a biosimilar to Prolia

Pharmacokinetic Properties

Absorption

Following subcutaneous administration, bioavailability was 62%.

Biotransformation

Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.

Elimination

In subjects with advanced cancer, who received multiple doses of 120 mg every 4 weeks an approximate 2-fold accumulation in serum Denosumab concentrations was observed and steady-state was achieved by 6 months, consistent with time-independent pharmacokinetics. In subjects with multiple myeloma who received 120 mg every 4 weeks, median trough levels varied by less than 8% between months 6 and 12. In subjects with giant cell tumour of bone who received 120 mg every 4 weeks with a loading dose on days 8 and 15, steady-state levels were achieved within the first month of treatment. Between weeks 9 and 49, median trough levels varied by less than 9%. In subjects who discontinued 120 mg every 4 weeks, the mean half-life was 28 days (range 14 to 55 days).

A population pharmacokinetic analysis did not indicate clinically significant changes in the systemic exposure of Denosumab at steady-state with respect to age (18 to 87 years), race/ethnicity (Blacks, Hispanics, Asians and Caucasians explored), gender or solid tumour types or patients with multiple myeloma. Increasing body weight was associated with decreases in systemic exposure, and vice versa. The alterations were not considered clinically-relevant, since pharmacodynamics effects based on bone turnover markers were consistent across a wide range of body weight.

Linearity/non-linearity

Denosumab displayed non-linear pharmacokinetics with dose over a wide dose range, but approximately dose-proportional increases in exposure for doses of 60 mg (or 1 mg/kg) and higher. The non-linearity is likely due to a saturable target-mediated elimination pathway of importance at low concentrations.

Renal impairment

In studies of Denosumab (60 mg, n = 55 and 120 mg, n = 32) in patients without advanced cancer but with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of Denosumab; thus dose adjustment for renal impairment is not required. There is no need for renal monitoring with Denosumab dosing.

Hepatic impairment

No specific study in patients with hepatic impairment was performed. In general, monoclonal antibodies are not eliminated via hepatic metabolic mechanisms. The pharmacokinetics of Denosumab is not expected to be affected by hepatic impairment.

Elderly

No overall differences in safety or efficacy were observed between geriatric patients and younger patients. Controlled clinical studies of Denosumab in patients with advanced malignancies involving bone over age 65 revealed similar efficacy and safety in older and younger patients. No dose adjustment is required in elderly patients.

Paediatric population

In skeletally-mature adolescents (12-17 years of age) with giant cell tumour of bone who received 120 mg every 4 weeks with a loading dose on days 8 and 15, the pharmacokinetics of Denosumab were similar to those observed in adult subjects with Giant Cell Tumor of Bone (GCTB).

Preclinical Safety Data

Since the biological activity of Denosumab in animals is specific to nonhuman primates, evaluation of genetically engineered (knockout) mice or use of other biological inhibitors of the RANK/RANKL pathway, such as OPG-Fc and RANK-Fc, were used to evaluate the pharmacodynamics properties of Denosumab in rodent models.

In mouse bone metastasis models of oestrogen receptor positive and negative human breast cancer, prostate cancer and non-small cell lung cancer, OPG-Fc reduced osteolytic, osteoblastic, and osteolytic/osteoblastic lesions, delayed formation of de novo bone metastases, and reduced skeletal

tumour growth. When OPG-Fc was combined with hormonal therapy (tamoxifen) or chemotherapy (docetaxel) in these models, there was additive inhibition of skeletal tumour growth in breast, and prostate or lung cancer respectively. In a mouse model of mammary tumour induction, RANK-Fc reduced hormone-induced proliferation in mammary epithelium and delayed tumour formation.

Standard tests to investigate the genotoxicity potential of Denosumab have not been evaluated, since such tests are not relevant for this molecule. However, due to its character it is unlikely that Denosumab has any potential for genotoxicity.

The carcinogenic potential of Denosumab has not been evaluated in long-term animal studies.

In single and repeated dose toxicity studies in cynomolgus monkeys, Denosumab doses resulting in 2.7 to 15 times greater systemic exposure than the recommended human dose had no impact on cardiovascular physiology, male or female fertility, or produced specific target organ toxicity.

In a study of cynomolgus monkeys dosed with denosumab during the period equivalent to the first trimester of pregnancy, denosumab doses resulting in 9 times greater systemic exposure than the recommended human dose did not induce maternal toxicity or foetal harm during a period equivalent to the first trimester, although foetal lymph nodes were not examined.

In another study of cynomolgus monkeys dosed with denosumab throughout pregnancy at systemic exposures 12-fold higher than the human dose, there were increased stillbirths and postnatal mortality; abnormal bone growth resulting in reduced bone strength, reduced haematopoiesis, and tooth malalignment; absence of peripheral lymph nodes; and decreased neonatal growth. A no observed adverse effect level for reproductive effects was not established. Following a 6 month period after birth, bone related changes showed recovery and there was no effect on tooth eruption. However, the effects on lymph nodes and tooth malalignment persisted, and minimal to moderate mineralisation in multiple tissues was seen in one animal (relation to treatment uncertain). There was no evidence of maternal harm prior to labour; adverse maternal effects occurred infrequently during labour. Maternal mammary gland development was normal.

In preclinical bone quality studies in monkeys on long-term denosumab treatment, decreases in bone turnover were associated with improvement in bone strength and normal bone histology.

In male mice genetically engineered to express huRANKL (knock-in mice), which were subjected to a transcortical fracture, denosumab delayed the removal of cartilage and remodelling of the fracture callus compared to control, but biomechanical strength was not adversely affected.

In preclinical studies knockout mice lacking RANK or RANKL had an absence of lactation due to inhibition of mammary gland maturation (lobulo-alveolar gland development during pregnancy) and exhibited impairment of lymph node formation. Neonatal RANK/RANKL knockout mice exhibited decreased body weight, reduced bone growth, altered growth plates and lack of tooth eruption. Reduced bone growth, altered growth plates and impaired tooth eruption were also seen in studies of neonatal rats administered RANKL inhibitors, and these changes were partially reversible when dosing of RANKL inhibitor was discontinued. Adolescent primates dosed with denosumab at 2.7 and 15 times (10 and 50 mg/kg dose) the clinical exposure had abnormal growth plates. Therefore, treatment with denosumab may impair bone growth in children with open growth plates and may inhibit eruption of dentition.

CLINICAL PARTICULARS

Therapeutic Indications

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with multiple myeloma and in patients with bone metastases from solid tumours.

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Dosage and Method of Administration

Vevzuo™ should be administered under the responsibility of a healthcare professional.

Dosage

Supplementation of at least 500 mg calcium and 400 IU vitamin D daily is required in all patients, unless hypercalcaemia is present ***(see section Special warnings and precautions for use)***.

Prevention of skeletal-related events in adults with multiple myeloma and bone metastasis from solid tumours

The recommended dose is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.

Giant cell tumour of bone

The recommended dose of Vevzuo™ is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm with additional 120 mg doses on days 8 and 15 of treatment of the first month of therapy.

Patients in the phase II study who underwent complete resection of giant cell tumour of bone did receive an additional 6 months of treatment following the surgery as per study protocol.

Patients with giant cell tumour of bone should be evaluated at regular intervals to determine whether they continue to benefit from treatment. In patients whose disease is controlled by Vevzuo™, the effect of interruption or cessation of treatment has not been evaluated, however limited data in these patients does not indicate a rebound effect upon cessation of treatment.

Renal impairment

No dose adjustment is required in patients with renal impairment ***(see section Special warnings and precautions for use for recommendations relating to monitoring of calcium, Undesirable effects and Pharmacokinetic properties)***.

Hepatic impairment

The safety and efficacy of Denosumab have not been studied in patients with hepatic impairment ***(see section Pharmacokinetic properties)***.

Elderly patients (age ≥ 65)

No dose adjustment is required in elderly patients ***(see section Pharmacokinetic properties)***.

Paediatric population

The safety and efficacy of Denosumab have not been evaluated in paediatric patients (age < 18) other than skeletally mature adolescents (aged 12-17 years) with giant cell tumour of bone.

Vevzuo™ is not recommended in paediatric patients (age < 18) other than skeletally mature adolescents (aged 12-17 years) with giant cell tumour of bone ***(see section Special warnings and precautions for use)***.

Treatment of skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity: the posology is the same as in adults.

Inhibition of RANK/RANK ligand (RANKL) in animal studies has been coupled to inhibition of bone growth and lack of tooth eruption, and these changes were partially reversible upon cessation of RANKL inhibition ***(see section Preclinical safety data)***.

Method of Administration

For subcutaneous use.

For instructions for use, handling and disposal ***(see section Special precautions for disposal and other handling)***.

Contraindications

Hypersensitivity to the active substance or to any of the excipients ***(see section Qualitative and Quantitative Composition***.

Severe, untreated hypocalcaemia ***(see section Special warnings and precautions for use)***.

Unhealed lesions from dental or oral surgery.

Special Warnings and Precautions for Use

Calcium and Vitamin D supplementation

Supplementation with calcium and vitamin D is required in all patients unless hypercalcaemia is present ***(see section Dosage and method of administration)***.

Hypocalcaemia

Pre-existing hypocalcaemia must be corrected prior to initiating therapy with Denosumab.

Hypocalcaemia can occur at any time during therapy with Denosumab. Monitoring of calcium levels should be conducted (i) prior to the initial dose of Denosumab, (ii) within two weeks after the initial dose, (iii) if suspected symptoms of hypocalcaemia occur ***(see section Undesirable effects for symptoms)***. Additional monitoring of calcium level should be considered during therapy in patients with risk factors for hypocalcaemia, or if otherwise indicated based on the clinical condition of the patient.

Patients should be encouraged to report symptoms indicative of hypocalcaemia. If hypocalcaemia occurs while receiving Denosumab, additional calcium supplementation and additional monitoring may be necessary.

In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported ***(see section Undesirable effects)***, with most cases occurring in the first weeks of initiating therapy, but can occur later.

Renal impairment

Patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis are at greater risk of developing hypocalcaemia. The risk of developing hypocalcaemia and accompanying elevations in parathyroid hormone increases with increasing degree of renal impairment. Regular monitoring of calcium levels is especially important in these patients.

Osteonecrosis of the Jaw (ONJ)

Osteonecrosis of the Jaw (ONJ) has been reported commonly in patients receiving Denosumab ***(see section Undesirable effects)***.

The start of treatment/new treatment course should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit risk assessment is recommended prior to treatment with Denosumab.

The following risk factors should be considered when evaluating a patient's risk of developing ONJ:

- Potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
- Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
- Concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck
- Poor oral hygiene, periodontal disease, poorly fitting dentures, pre-existing dental disease, invasive dental procedures (e.g. tooth extractions).

All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or

Product Name	VEVZUO 120 MG	**Component :**	PIL
Size	Size: 476 (W) mm x 775 (H) mm Folded size: 98(W) x 40(H) mm Patient Information Card Size : 95(L) x 36(H)mm	**Artwork code :**	BFXXXXX/XX
Pharmacode	NA	**Country :**	MALAYASIA
Font type	Helvetica Neue LT Pro	**Specification :** Paper : 40gsm ITC news print	
Font size	10 pt		
Colours	KEYLINE BLACK		

X:\ARTWORKS\DENOSUMAB\MALAYSIA - EVFRAXY & VEVZUO\ BFXXXXX-XX- VEVZUO LEAFLET - MALAYSIA
13.03.2026 V1 | 21.04.2026 V2 | 29.04.2026 V3

discharge during treatment with Denosumab. While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Denosumab administration.

The management plan of the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of Denosumab treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.

Osteonecrosis of the external auditory canal

Osteonecrosis of the external auditory canal has been reported with Denosumab. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving Denosumab who present with ear symptoms including chronic ear infections.

Atypical fractures of the femur

Atypical femoral fractures have been reported in patients receiving Denosumab ***(see section Undesirable effects)***. Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur. Specific radiographic findings characterise these events. Atypical femoral fractures have also been reported in patients with certain co-morbid conditions (e.g., vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (e.g., bisphosphonates, glucocorticoids, and proton pump inhibitors). These events have also occurred without antiresorptive therapy. Similar fractures reported in association with bisphosphonates are often bilateral; therefore the contralateral femur should be examined in Denosumab -treated patients who have sustained a femoral shaft fracture. Discontinuation of Denosumab therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit-risk assessment. During Denosumab treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture.

Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone and in patients with growing skeletons

Clinically significant hypercalcaemia requiring hospitalisation and complicated by acute renal injury has been reported in Denosumab -treated patients with giant cell tumour of bone weeks to months following treatment discontinuation.

After treatment is discontinued, monitor patients for signs and symptoms of hypercalcaemia, consider periodic assessment of serum calcium and re-evaluate the patient's calcium and vitamin D supplementation requirements ***(see section Undesirable effects)***.

Denosumab is not recommended in patients with growing skeletons ***(see section Dosage and method of administration)***. Clinically significant hypercalcaemia has also been reported in this patient group weeks to months following treatment discontinuation.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation

Multiple vertebral fractures (MVF), not due to bone metastases, may occur following discontinuation of treatment with Denosumab, particularly in patients with risk factors such as osteoporosis or prior fractures. Advise patients not to interrupt Denosumab therapy without their physician's advice. When Denosumab treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.

Others

Denosumab contains the same active ingredient as found in Evfraxy (Denosumab). Patients being treated with Denosumab should not be treated concomitantly with other Denosumab containing medicinal products (for osteoporosis indications).

Patients being treated with Denosumab should not be treated concomitantly with bisphosphonates.

Warnings for excipients

This medicinal product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.

This medicinal product contains less than 1 mmol sodium (23 mg) per 120 mg, i.e. essentially 'sodium-free'.

Interactions with Other Medicaments

No interaction studies have been performed.

In clinical trials, Denosumab has been administered in combination with standard anti-cancer treatment and in subjects previously receiving bisphosphonates. There were no clinically-relevant alterations in trough serum concentration and pharmacodynamics of Denosumab (creatinine adjusted urinary N-telopeptide, uNTx/Cr) by concomitant chemotherapy and/or hormone therapy or by previous intravenous bisphosphonate exposure.

Fertility, Pregnancy and Lactation

Pregnancy

There are no adequate data from the use of Denosumab in pregnant women. Reproductive toxicity was shown in a study of cynomolgus monkeys, dosed throughout pregnancy with Denosumab at AUC exposures 12-fold higher than the human dose ***(see section Preclinical safety data)***.

Denosumab is not recommended for use in pregnant women and women of childbearing potential not using contraception. Women should be advised not to become pregnant during and for at least 5 months after treatment with Denosumab. Any effects of Denosumab are likely to be greater during the second and third trimesters of pregnancy since monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester.

Breast-feeding

It is unknown whether Denosumab is excreted in human milk. A risk to the newborns/infants cannot be excluded. Knockout mouse studies suggest absence of RANKL during pregnancy may interfere with maturation of the mammary gland leading to impaired lactation post-partum ***(see section Preclinical safety data)***. A decision must be made on whether to abstain from breast-feeding or to abstain from Denosumab therapy taking into account the benefit of breast-feeding to the newborn/infant and the benefit of therapy for the woman.

Fertility

No data are available on the effect of Denosumab on human fertility. Animal studies do not indicate direct or indirect harmful effects with respect to fertility ***(see section Preclinical safety data)***.

Undesirable Effects

Summary of the safety profile

Overall safety profile is consistent in all approved indications for Vevzuo™.

Hypocalcaemia has very commonly been reported following Vevzuo™ administration, mostly within the first 2 weeks. Hypocalcaemia can be severe and symptomatic ***(see section Undesirable effects - description of selected adverse reactions)***. The decreases in serum calcium were generally appropriately managed by calcium and vitamin D supplementation. The most common adverse reactions with Vevzuo™ are musculoskeletal pain. Cases of osteonecrosis of the jaw ***(see sections Special warnings and precautions for use and section Undesirable effects – description of selected adverse reactions)*** have been commonly observed in patients taking Vevzuo™.

Tabulated list of adverse reactions

The following convention has been used for the classification of the adverse reactions based on incidence rates in four phase III, two phase II clinical studies and post-marketing experience are presented in Table 3: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data. Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.

Table 3: Adverse reactions reported in patients with advanced malignancies involving bone, multiple myeloma, or with giant cell tumour of bone

MedDRA system organ class	Frequency category	Adverse reactions
Neoplasms benign, malignant and unspecified (including cysts and polyps)	Common	New primary malignancy1
Immune system disorders	Rare	Drug hypersensitivity1
	Rare	Anaphylactic reaction1
Metabolism and nutrition disorders	Very common	Hypocalcaemia[1, 2]
	Common	Hypophosphataemia
	Uncommon	Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone[2]
Respiratory, thoracic and mediastinal disorders	Very common	Dyspnoea
Gastrointestinal disorders	Very common	Diarrhoea
	Common	Tooth extraction
Skin and subcutaneous tissue disorders	Common	Hyperhidrosis
	Common	Alopecia
	Uncommon	Lichenoid drug eruptions1
Musculoskeletal and connective tissue disorders	Very Common	Musculoskeletal pain1
	Common	Osteonecrosis of the jaw1
	Uncommon	Atypical femoral fracture1
	Rare	Multiple vertebral fractures following treatment discontinuation[1, 3]
	Not known	Osteonecrosis of the external auditory canal[3, 4]

1 See section Description of selected adverse reactions

2 See section other special populations

3 See section Special warnings and precautions for use

4 Class effect

Description of selected adverse reactions

Hypocalcaemia

A higher incidence of hypocalcaemia among subjects treated with Denosumab compared to Zoledronic Acid has been observed in SRE prevention clinical trials.

The highest incidence of hypocalcaemia was observed in a phase III trial in patients with multiple myeloma. Hypocalcaemia was reported in 16.9% of patients treated with Denosumab and 12.4% of patients treated with Zoledronic Acid. A grade 3 decrease in serum calcium levels was experienced in 1.4% of patients treated with Denosumab and 0.6% of patients treated with Zoledronic Acid. A grade 4 decrease in serum calcium levels was experienced in 0.4% of patients treated with Denosumab and 0.1% of patients treated with Zoledronic Acid.

In three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, hypocalcaemia was reported in 9.6% of patients treated with Denosumab and 5.0% of patients treated with Zoledronic Acid.

A grade 3 decrease in serum calcium levels was experienced in 2.5% of patients treated with Denosumab and 1.2% of patients treated with Zoledronic Acid. A grade 4 decrease in serum calcium levels was experienced in 0.6% of patients treated with Denosumab and 0.2% of patients treated with Zoledronic Acid ***(see section Special warnings and precautions for use)***.

In two phase II single-arm clinical trials in patients with giant cell tumour of bone, hypocalcaemia was reported in 5.7% of patients. None of the adverse events was considered serious.

In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported, with most cases occurring in the first weeks of initiating therapy. Examples of clinical manifestations of severe symptomatic hypocalcaemia have included QT interval prolongation, tetany, seizures and altered mental status (including coma) ***(see section Special warnings and precautions for use)***. Symptoms of hypocalcaemia in clinical studies included paraesthesias or muscle stiffness, twitching, spasms and muscle cramps.

Osteonecrosis of the Jaw (ONJ)

In clinical trials, the incidence of ONJ was higher with longer duration of exposure; ONJ has also been diagnosed after stopping treatment with Denosumab with the majority of cases occurring within 5 months after the last dose. Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned invasive dental procedure were excluded from the clinical trials.

A higher incidence of ONJ among subjects treated with Denosumab compared to Zoledronic Acid has been observed in SRE prevention clinical trials. The highest incidence of ONJ was observed in a phase III trial in patients with multiple myeloma. In the double-blind treatment phase of this trial, ONJ was confirmed in 5.9% of patients treated with Denosumab (median exposure of 19.4 months; range 1 - 52) and in 3.2% of patients treated with zolendronic acid. At the completion of the double-blind treatment phase of this trial, the patient-year adjusted incidence of confirmed ONJ in the Denosumab group (median exposure of 19.4 months; range 1 - 52), was 2.0 per 100 patient-years during the first year of treatment, 5.0 in the second year, and 4.5 thereafter. The median time to ONJ was 18.7 months (range: 1 - 44).

In the primary treatment phases of three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, ONJ was confirmed in 1.8% of patients treated with Denosumab (median exposure of 12.0 months; range 0.1 – 40.5) and 1.3% of patients in the Zoledronic Acid. Clinical characteristics of these cases were similar between treatment groups. Among subjects with confirmed ONJ, most (81% in both treatment groups) had a history of tooth extraction, poor oral hygiene, and/or use of a dental appliance. Most subjects were receiving or had received chemotherapy.

The trials in patients with breast or prostate cancer included a Denosumab extension treatment phase (median overall exposure of 14.9 months; range 0.1 – 67.2). ONJ was confirmed in 6.9% of patients with breast cancer and prostate cancer during the extension treatment phase.

The patient-year adjusted overall incidence of confirmed ONJ was 1.1 per 100 patient-years during the first year of treatment, 3.7 in the second year and 4.6 thereafter. The median time to ONJ was 20.6 months (range: 4 - 53).

In a phase III trial in patients with non-metastatic prostate cancer (a patient population for which Denosumab is not indicated), with longer treatment exposure of up to 7 years, the patient-year adjusted incidence of confirmed ONJ was 1.1per 100 patient-years during the first year of treatment, 3.0 in the second year and 7.1 thereafter.

In a long-term phase II open-label clinical trial in patients with giant cell tumour of bone in Study 6 ***(see section Pharmacodynamic properties)***, ONJ was confirmed in 6.8% of patients, including one adolescent (median number of 34 doses; range 4 – 116). At the completion of the trial, median time on trial including safety follow-up phase was 60.9 months (range: 0 – 112.6). The patient-year adjusted incidence of confirmed ONJ was 1.5 per 100 patient-years overall (0.2 per 100 patient-years during the first year of treatment, 1.5 in the second year, 1.8 in the third year, 2.1 in the fourth year, 1.4 in the fifth year, and 2.2 thereafter). The median time to ONJ was 41 months (range: 11 - 96).

Drug related hypersensitivity reactions

In the post-marketing setting, events of hypersensitivity, including rare events of anaphylactic reactions, have been reported in patients receiving Denosumab.

Atypical fractures of the femur

In the clinical trial programme, atypical femoral fractures have been reported uncommonly in patients treated with Denosumab and the risk increased with longer duration of treatment. Events have occurred during treatment and up to 9 months after the treatment was discontinued ***(see section Special warnings and precautions for use)***.

Multiple vertebral fractures

In the clinical trial program, multiple vertebral fractures, (not due to bone metastases), were reported rarely, following discontinuation of treatment with Denosumab, in patients with risk factors such as osteoporosis or prior (non-vertebral or vertebral) fractures ***(see section Special warnings and precautions for use)***.

Musculoskeletal Pain

In the post-marketing setting, musculoskeletal pain, including severe cases, has been reported in patients receiving Denosumab. In clinical trials, musculoskeletal pain was very common in both the Denosumab and Zoledronic Acid treatment groups. Musculoskeletal pain leading to discontinuation of study treatment was uncommon.

New primary malignancy

In the primary double-blind treatment phases of four phase III active-controlled clinical trials in patients with advanced malignancies involving bone, new primary malignancy was reported in 54/3691 (1.5%) of patients treated with Denosumab (median exposure of 13.8 months; range: 1.0–51.7) and 33/3688 (0.9%) of patients treated with Zoledronic Acid (median exposure of 12.9 months; range: 1.0-50.8).

The cumulative incidence at one year was 1.1 % for Denosumab and 0.6 % for Zoledronic Acid, respectively.

No treatment-related pattern in individual cancers or cancer groupings was apparent.

Lichenoid Drug Eruptions

In the post-marketing experience, lichenoid drug eruptions (e.g., lichen planus-like reactions) have been observed.

Paediatric population

Denosumab was studied in an open label trial that enrolled 28 skeletally mature adolescents with giant cell tumour of bone. Based on these limited data, the adverse event profile appeared to be similar to adults.

Clinically significant hypercalcaemia after treatment discontinuation has been reported in the postmarketing setting in paediatric patients ***(see section Special warnings and precautions for use)***.

Other special populations

Renal Impairment

In a clinical study of patients without advanced cancer with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis, there was a greater risk of developing hypocalcaemia in the absence of calcium supplementation. The risk of developing hypocalcaemia during Denosumab treatment is greater with increasing degree of renal impairment. In a clinical study in patients without advanced cancer, 19% of patients with severe renal impairment (creatinine clearance < 30 mL/min) and 63% of patients receiving dialysis developed hypocalcaemia despite calcium supplementation. The overall incidence of clinically significant hypocalcaemia was 9%.

Accompanying increases in parathyroid hormone have also been observed in patients receiving Denosumab with severe renal impairment or receiving dialysis. Monitoring of calcium levels and adequate intake of calcium and vitamin D is especially important in patients with renal impairment ***(see section Special warnings and precautions for use)***.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions as per local regulations.

Overdose

There is no experience with overdose clinical studies. Denosumab has been administered in clinical studies using doses up to 180 mg every 4 weeks and 120 mg weekly for 3 weeks.

Ability to Drive and Use Machines

Vevzuo™ has no or negligible influence on the ability to drive and use machines.

Special precautions for storage

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light. Do not shake.

Once removed from the refrigerator, Vevzuo™ may be stored at room temperature (up to 25°C) for up to 30 days in the original container.

Nature and Contents of Container

1.7 mL solution (70 mg/mL) in a single use vial (Type I glass) with chlorobutyl rubber stoppers (Flurotec® coated) and sealed with clear flip-off aluminium seal.

Pack size of one.

Shelf Life

Refer to Carton/Label.

Instructions for Use

Special Precautions for Disposal and Other Handling

- Before administration, the Vevzuo™ solution should be inspected visually. Do not inject the solution if it is cloudy or discoloured.
- Do not shake.
- To avoid discomfort at the site of injection, allow the vial to reach room temperature (up to 25°C) before injecting and inject slowly.
- The entire contents of the vial should be injected.
- A 27 gauge needle is recommended for the administration of Vevzuo™.
- The vial should not be re-entered.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

1. Product Registration Holder:

Biocon Sdn. Bhd.

No. 1, Jalan Bioteknologi 1, Kawasan Perindustrian SiLC, 79200, Iskandar Puteri, Johor, Malaysia.

2. Manufacturer & Batch Releaser:

Biocon Biologics Limited

Block No. B1, B2, B3, Q13 of Q1 and W20 & Unit S18, 1st Floor, Block B4, Special Economic Zone, Plot No. 2, 3, 4 & 5, Phase IV Bommasandra-Jigani Link Road, Bommasandra, Bengaluru - 560099, India.

3. Importer & Distributor:

Duopharma HAPI Sdn. Bhd.

No. 2, Jalan Saudagar U1/16, Pusat Perindustrian Hicom Glenmarie, Seksyen U1, 40150 Shah Alam, Selangor, Malaysia

4. Date of Revision: April 2026

DUOPHARMA

NO TEXT AREA
NO PRINTING PANEL FOR PASTING
NO PRINTING PANEL FOR PASTING
NO TEXT